Rituximab-Belimumab Sequential Therapy in Refractory Minimal Change Disease. (PubMed, Kidney360) - Oct 16, 2026 - "A 14-year-old male with biopsy-proven MCD and acute kidney injury failed multiple immunosuppressants, including two courses of rituximab (the first induced a 6-month remission, whereas the second failed despite B-cell depletion). After another relapse, he received single-dose rituximab followed by belimumab, achieving complete remission and maintaining relapse-free for 57 months.This case suggests that sequential rituximab-belimumab therapy may offer durable remission in MCD patients who are refractory to conventional immunosuppressive regimens."
Journal • Acute Kidney Injury • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Nephrology • Renal Disease
|
|
Jinbo Cheng; Yifan Li; Yinghui Huang; Yuxin Ai
|